Background COVID-19 may spread through various ways ranging from asymptomatic to
severe forms, until respiratory failure, critical conditions and death occurs. There is a …

Across its clinical development program, ocrelizumab demonstrated efficacy in improving
clinical outcomes in multiple sclerosis, including annualized relapse rates and confirmed …

Data regarding effectiveness and safety of ocrelizumab in the post-marking setting are
lacking. The aim of our study was to provide effectiveness and safety data of ocrelizumab …

Ocrelizumab is a recombinant humanized monoclonal antibody selectively targeting CD20-
expressing B cells. The effect of ocrelizumab on primary progressive multiple sclerosis …

Background Ocrelizumab safety outcomes have been well evaluated in clinical trials and
open-label extension (OLE) studies. However, risk factors for infection in patients with …

Background and purpose Real‐world evidence regarding the effectiveness and safety of
ocrelizumab for the treatment of multiple sclerosis (MS) is limited. The aim was to evaluate …

The SARS-CoV-2 pandemic has raised particular concern for people with Multiple Sclerosis,
as these people are believed to be at increased risk of infection, especially those being …

Background Progressive multiple sclerosis (PMS) is a debilitating condition characterized by
progressively worsening symptoms. Monoclonal antibodies are novel therapies for MS, but …

Introduction Much of the current literature on treatment patterns and disability progression in
multiple sclerosis (MS) does not distinguish between the relapsing–remitting and …

Introduction We sought to assess adherence to and persistence with ocrelizumab (OCR)
compared with other disease-modifying treatments (DMTs), by route of administration (RoA) …